Bashar Hamad

599 total citations
15 papers, 460 citations indexed

About

Bashar Hamad is a scholar working on Economics and Econometrics, Pharmacology and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, Bashar Hamad has authored 15 papers receiving a total of 460 indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Economics and Econometrics, 3 papers in Pharmacology and 3 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in Bashar Hamad's work include Pharmaceutical Economics and Policy (3 papers), Venous Thromboembolism Diagnosis and Management (3 papers) and Antiplatelet Therapy and Cardiovascular Diseases (2 papers). Bashar Hamad is often cited by papers focused on Pharmaceutical Economics and Policy (3 papers), Venous Thromboembolism Diagnosis and Management (3 papers) and Antiplatelet Therapy and Cardiovascular Diseases (2 papers). Bashar Hamad collaborates with scholars based in United Kingdom, United States and Austria. Bashar Hamad's co-authors include Xiaoxiao Qian, Kurt Huber, Peter Kirkpatrick, Basharut A. Syed, Uma Yasothan, Rami A. Al‐Horani, Peter J. Kirkpatrick, Jalal K. Ghali, Ian Sander and Nuno Damácio de Carvalho Félix and has published in prestigious journals such as Nature Reviews Drug Discovery and Hospital Pharmacy.

In The Last Decade

Bashar Hamad

14 papers receiving 448 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Bashar Hamad United Kingdom	11	145	89	68	58	53	15	460
Jiabin Li China	14	204 1.4×	97 1.1×	56 0.8×	35 0.6×	12 0.2×	53	577
Fréderic Bounoure France	16	143 1.0×	34 0.4×	17 0.3×	56 1.0×	12 0.2×	39	632
Sharron Stewart United States	15	187 1.3×	38 0.4×	26 0.4×	16 0.3×	16 0.3×	30	559
Yitao Duan China	16	278 1.9×	25 0.3×	44 0.6×	39 0.7×	49 0.9×	25	593
Der‐Yuan Wang Taiwan	17	168 1.2×	36 0.4×	10 0.1×	29 0.5×	31 0.6×	53	673
Takako Kubota Japan	11	68 0.5×	50 0.6×	106 1.6×	90 1.6×	36 0.7×	24	429
Tapan K. Mukherjee India	14	239 1.6×	39 0.4×	64 0.9×	29 0.5×	7 0.1×	25	670
Joan B. Tarloff United States	13	205 1.4×	53 0.6×	10 0.1×	56 1.0×	18 0.3×	25	785
Zahoor Qadir Samra Pakistan	13	114 0.8×	24 0.3×	31 0.5×	54 0.9×	23 0.4×	32	482

Countries citing papers authored by Bashar Hamad

Since Specialization

Citations

This map shows the geographic impact of Bashar Hamad's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bashar Hamad with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bashar Hamad more than expected).

Fields of papers citing papers by Bashar Hamad

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bashar Hamad. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bashar Hamad. The network helps show where Bashar Hamad may publish in the future.

Co-authorship network of co-authors of Bashar Hamad

This figure shows the co-authorship network connecting the top 25 collaborators of Bashar Hamad. A scholar is included among the top collaborators of Bashar Hamad based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bashar Hamad. Bashar Hamad is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

1.

Hamad, Bashar, et al.. (2025). Impact of Clinical Pharmacists’ Interventions on Medication Use and Direct Cost Savings in an Inpatient Medical Oncology Setting. Hospital Pharmacy. 61(1). 89–95.

2.

Al‐Horani, Rami A., et al.. (2024). The pipeline and market for psoriasis drugs. Nature Reviews Drug Discovery. 23(7). 492–493. 5 indexed citations

3.

Al‐Horani, Rami A., et al.. (2021). The market for ulcerative colitis. Nature Reviews Drug Discovery. 21(1). 15–16. 22 indexed citations

4.

Sander, Ian, et al.. (2019). Gene therapies in ophthalmic disease. Nature Reviews Drug Discovery. 18(6). 415–416. 23 indexed citations

5.

Hamad, Bashar, et al.. (2018). The market for oral anticoagulants. Nature Reviews Drug Discovery. 17(9). 617–618. 12 indexed citations

6.

Hamad, Bashar, et al.. (2017). The atopic dermatitis market. Nature Reviews Drug Discovery. 17(4). 237–238. 15 indexed citations

7.

Félix, Nuno Damácio de Carvalho, et al.. (2016). The HIV therapy market. Nature Reviews Drug Discovery. 15(7). 451–452. 19 indexed citations

8.

Qian, Xiaoxiao, et al.. (2015). The Alzheimer disease market. Nature Reviews Drug Discovery. 14(10). 675–676. 43 indexed citations

9.

Esencay, Mine & Bashar Hamad. (2015). The chronic lymphocytic leukaemia market. Nature Reviews Drug Discovery. 14(6). 381–382. 4 indexed citations

10.

Syed, Basharut A. & Bashar Hamad. (2014). The cystic fibrosis drug market. Nature Reviews Drug Discovery. 13(10). 721–722. 5 indexed citations

11.

Hamad, Bashar, et al.. (2014). Antithrombotic drugs market. Nature Reviews Drug Discovery. 13(8). 571–572. 26 indexed citations

12.

Huber, Kurt, Bashar Hamad, & Peter Kirkpatrick. (2011). Ticagrelor. Nature Reviews Drug Discovery. 10(4). 255–256. 24 indexed citations

13.

Hamad, Bashar. (2010). The antibiotics market. Nature Reviews Drug Discovery. 9(9). 675–676. 219 indexed citations

14.

Ghali, Jalal K., Bashar Hamad, Uma Yasothan, & Peter J. Kirkpatrick. (2009). Tolvaptan. Nature Reviews Drug Discovery. 8(8). 611–612. 27 indexed citations

15.

Huber, Kurt, Uma Yasothan, Bashar Hamad, & Peter Kirkpatrick. (2009). Prasugrel. Nature Reviews Drug Discovery. 8(6). 449–450. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact